NOVN.SW
Price:
$112.04
Market Cap:
$260.94B
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with...[Read more]
Industry
Drug Manufacturers - General
IPO Date
1996-03-08
Stock Exchange
SIX
Ticker
NOVN.SW
According to Novartis AG’s latest financial reports and current stock price. The company's current ROE is 29.64%. This represents a change of 297.62% compared to the average of 7.45% of the last 4 quarters.
The mean historical ROE of Novartis AG over the last ten years is 20.87%. The current 29.64% ROE has changed 42.00% with respect to the historical average. Over the past ten years (40 quarters), NOVN.SW's ROE was at its highest in in the December 2021 quarter at 24.10%. The ROE was at its lowest in in the December 2016 quarter at 1.28%.
Average
20.87%
Median
18.60%
Minimum
8.97%
Maximum
35.51%
Discovering the peaks and valleys of Novartis AG ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 171.51%
Maximum Annual ROE = 35.51%
Minimum Annual Increase = -66.99%
Minimum Annual ROE = 8.97%
| Year | ROE | Change |
|---|---|---|
| 2025 | 31.78% | 17.22% |
| 2024 | 27.11% | -14.80% |
| 2023 | 31.82% | 171.51% |
| 2022 | 11.72% | -66.99% |
| 2021 | 35.51% | 148.95% |
| 2020 | 14.26% | -32.56% |
| 2019 | 21.15% | 31.84% |
| 2018 | 16.04% | 54.46% |
| 2017 | 10.39% | 15.79% |
| 2016 | 8.97% | -61.14% |
The current ROE of Novartis AG (NOVN.SW) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
30.24%
5-year avg
27.59%
10-year avg
20.87%
Novartis AG’s ROE is less than Roche Holding AG (37.12%), less than Abbott Laboratories (10.52%), greater than Cosmo Pharmaceuticals N.V. (-1.21%), less than Sandoz Group AG (7.04%), less than Siegfried Holding AG (16.14%), less than IVF Hartmann Holding AG (13.03%), less than Galenica AG (11.00%), less than Zimmer Biomet Holdings, Inc. (6.36%), less than COLTENE Holding AG (15.21%),
| Company | ROE | Market cap |
|---|---|---|
| 37.12% | $256.55B | |
| 10.52% | $125.45B | |
| -1.21% | $1.01B | |
| 7.04% | $28.88B | |
| 16.14% | $3.10B | |
| 13.03% | $309.58M | |
| 11.00% | $4.13B | |
| 6.36% | $14.99B | |
| 15.21% | $273.67M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novartis AG using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Novartis AG or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Novartis AG's ROE?
How is the ROE calculated for Novartis AG (NOVN.SW)?
What is the highest ROE for Novartis AG (NOVN.SW)?
What is the 3-year average ROE for Novartis AG (NOVN.SW)?
What is the 5-year average ROE for Novartis AG (NOVN.SW)?
How does the current ROE for Novartis AG (NOVN.SW) compare to its historical average?